Preview

Medical Herald of the South of Russia

Advanced search

THE COMPLEX INTENSIVE THERAPY INCLUDING APPLICATION EPOETIN ALFA AT THE SERIOUS СONCOMITANT BRAIN INJURY

https://doi.org/10.21886/2219-8075-2013-1-33-36

Abstract

Purpose: To reveal clinical effects of epoetin alfa in the sharp period the serious сoncomitant brain injury.

Materials and Methods: Controllable blind randomized research at 77 patients at the age of 38,6±15,2 years old was held. Epoetin alfa was entered intravenously. The given preparation was applied from first days of the posttraumatic period, in a course dose not less than 50000 МЕ (on 10000 МЕ within 5 days).

Results: The given preparation has reduced number of patients with a Multiple organ dysfunction syndrome, grasping infringements of functions of three and more bodies (in 1,7 times). In group of patients by which it was applied epoetin alfa, the number of complications has decreased from bronho-pulmonary system. The number of cases respiratory distress has decreased in 2,1 times, pneumonia - in 3 times, trophic infringements - in 5,5 times.

Summary: Inclusion in intensive therapy the serious сoncomitant brain injury epoetin alfa leads to more favorable current of traumatic illness. 

About the Authors

E. A. Lebedeva
Rostov State Medical University
Russian Federation

Anesthesiology and Intensive Care Department with a Course of Toxicology

29 Nakhichevansky st., Rostov-on-Don, 344022


A. A. Kurtasov
Rostov State Medical University
Russian Federation

Anesthesiology and Intensive Care Department with a Course of Toxicology

29 Nakhichevansky st., Rostov-on-Don, 344022


Z. A. Nemkova
Rostov State Medical University
Russian Federation

Anesthesiology and Intensive Care Department with a Course of Toxicology

29 Nakhichevansky st., Rostov-on-Don, 344022


References

1. Бакшеев, В.И. Эритропоэтин в клинической практике: прошлое, настоящее и будущее (обзор литературы) / В.И. Бакшеев, Н.М. Коломоец // Клиническая медицина. – 2007. – № 9. – С. 30-37.

2. Xu, B. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappaB / B. Xu, G.H. Dong, H. Liu et al. // Ann. Clin. Lab. Sci. – 2005. – Vol. 35(2). -Р. 161-168.

3. Fliser, D. Mechanisms of disease: erythropoietin-an old hormone with a new mission? / D. Fliser, F.H. Bahlmann, K. de Groot, H. Haller // Nat. Clin. Pract. Cardiovasc. Med. - 2006. - Vol. 3(10). - Р. 563-572.

4. Sepodes, B. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat / B. Sepodes, R. Maio, R. Pinto et al. // Transpl. Int. – 2006. – Vol. 19(11). – Р. 919–926.

5. Chong, Z.Z. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease / Z.Z. Chong, F. Li, K. Maiese // Prog. Neurobiol. – 2005. – Vol. 75(3). – Р. 207–246.

6. Corwin, H.L. Critical Care Trials Group. Efficacy and safety of epoetin alfa in critically ill patients / H.L. Corwin, A. Gettinger, T.C. Fabian et al. // N. Engl. J. Med. – 2007. – Vol. 357(10). – P. 1037–1039.

7. Moore, E.M. Erythropoietin as a novel brain and kidney protective agent / E.M. Moore, R. Bellomo, A.D. Nichol // Anaesth. Intensive Care. – 2011. – Vol. 39(3). – P. 356–372.

8. Teasdale, G. Assessment of coma and impaired consciousness. A practical scale / G. Teasdale, B. Jennett // Lancet. – 1974. – Vol. 2. – P. 81–84.

9. Цыбуляк, Г.Н. Лечение тяжелых и сочетанных повреждений / Г.Н. Цыбуляк. – СПб.: Гиппократ, 1995. – 432 с.

10. Лебедева, Е.А. Пролонгированные эффекты эритропоэтина при использовании его в процессе интенсивной терапии сочетанной черепно-мозговой травмы / Е.А. Лебедева // Вестник неврологии, психиатрии и нейрохирургии. – 2012. – № 2. – С. 43–47.


Review

For citations:


Lebedeva E.A., Kurtasov A.A., Nemkova Z.A. THE COMPLEX INTENSIVE THERAPY INCLUDING APPLICATION EPOETIN ALFA AT THE SERIOUS СONCOMITANT BRAIN INJURY. Medical Herald of the South of Russia. 2013;(1):33-36. (In Russ.) https://doi.org/10.21886/2219-8075-2013-1-33-36

Views: 830


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2219-8075 (Print)
ISSN 2618-7876 (Online)